SHR0302 increased Tregs and reduced Th1 cells. (A) The cell counts of
bone marrow (BM) and spleen in 4 group mice: vehicle-6Ws, SHR0302-16Ws,
TCD-BMT-6Ws, and healthy recipient control (n = 9 for
each group) (6Ws and 16Ws: at 6th and 16th weeks after transplantation,
respectively). (B) The percentages of CD3+ T cells and
CD19+ B cells in spleen cells in four groups: vehicle-6Ws
(n = 10), SHR0302-16Ws (n = 11),
TCD-BMT-6Ws (n = 9), and healthy recipient control
(n = 9). (C) The percentages of CD4+ T
cells and CD8+ T cells in all T cells of spleen in four
groups: vehicle-6Ws (n = 10), SHR0302-16Ws
(n = 11), TCD-BMT-6Ws (n = 9), and
healthy recipient control group (n = 9). (D) The
percentages of CD4+Foxp3+ cells of spleen in
vehicle-6Ws (n = 7), SHR0302-16Ws (n =
11), TCD-BMT-6Ws (n = 9), and healthy recipient control
groups (n = 9), respectively. (E) The percentages of
CD4+IFN-γ+ cells in all CD4+ cells
of spleen in four groups: vehicle-6Ws (n = 5),
SHR0302-16Ws (n = 5), TCD-BMT-6Ws (n =
3), and healthy recipient control (n = 3). (F) The
percentages of CD8+IFN-γ+ cells in all
CD8+ cells of spleen in four groups: vehicle-6Ws
(n = 5), SHR0302-16Ws (n = 5),
TCD-BMT-6Ws (n = 3), and healthy recipient control mice
(n = 3). Data were pooled from two separate
experiments in Figure A-D. Bars show the mean ± SEM. *P
< 0.05.